Haleon PLC Holding(s) in Company
04 October 2024 - 11:30PM
RNS Regulatory News
RNS Number : 0456H
Haleon PLC
04 October 2024
4 October 2024
HALEON
PLC
("Haleon"
or "the Company")
TR-1:
Standard form for notification of major holdings
2.
Reason for Notification
An acquisition or disposal of voting
rights
3.
Details of person subject to the notification
obligation
City
of registered office (if applicable)
Country of registered office (if applicable)
4.
Details of the shareholder
|
Name
|
City
of registered office
|
Country of registered office
|
|
State Street Nominees
Limited
|
London
|
United Kingdom
|
|
Guaranty Nominees Limited
|
London
|
United Kingdom
|
5.
Date on which the threshold was crossed or
reached
6.
Date on which Issuer notified
7.
Total positions of person(s) subject to the notification
obligation
|
|
% of
voting rights attached to shares (total of 8.A)
|
% of
voting rights through financial instruments (total of 8.B 1 + 8.B
2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer
|
|
Resulting situation on the date on
which threshold was crossed or reached
|
15.040000
|
0.000000
|
15.040000
|
1361709764
|
|
Position of previous notification
(if applicable)
|
22.580000
|
0.000000
|
22.580000
|
|
8.
Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A.
Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of
direct voting rights (DTR5.1)
|
% of
indirect voting rights (DTR5.2.1)
|
|
Ordinary Shares
GB00BMX86B70
|
|
967251860
|
|
10.680000
|
|
Restricted ADSs
|
|
394457904
|
|
4.360000
|
|
Sub Total 8.A
|
1361709764
|
15.040000%
|
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type
of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument
is exercised/converted
|
% of
voting rights
|
|
|
|
|
|
|
|
Sub Total 8.B1
|
|
|
|
8B2. Financial Instruments with similar economic effect
according to (DTR5.3.1R.(1) (b))
|
Type
of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of
voting rights
|
|
|
|
|
|
|
|
|
Sub Total 8.B2
|
|
|
|
9.
Information in relation to the person subject to the notification
obligation
1. Person subject to the notification
obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer.
|
Ultimate controlling person
|
Name
of controlled undertaking
|
% of
voting rights if it equals or is higher than the notifiable
threshold
|
% of
voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
|
|
|
|
|
10.
In case of proxy voting
The
number and % of voting rights held
The
date until which the voting rights will be held
11.
Additional Information
This notification relates to the sale
by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon
plc ("Haleon").
Pfizer sold 640,000,000 Haleon ordinary shares
("Ordinary Shares") pursuant to a secondary offering announced on
30 September 2024. In connection with the offering, and in addition
to the 640,000,000 Ordinary Shares in the offering, Pfizer sold
60,526,315 Ordinary Shares to Haleon in an off-market sale in
accordance with the terms of a share purchase deed between Haleon
and Pfizer that was previously approved by Haleon's
shareholders.
These calculations are based on Haleon's issued
voting share capital of 9,053,360,882 ordinary shares with voting
rights, as communicated by Haleon in their announcement on total
voting rights and capital dated 3 October 2024.
Pfizer holds its ordinary shares in Haleon through
(i) State Street Nominees Limited, and (ii) Guaranty Nominees
Limited (in respect of its American depositary shares representing
Ordinary Shares), which hold the legal title to those shares on
Pfizer's behalf.
Amanda Mellor, Company Secretary
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
HOLUSVURSBURRAA
Haleon (LSE:HLN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Haleon (LSE:HLN)
Historical Stock Chart
From Nov 2023 to Nov 2024
